id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-D-1536-0037,FDA,FDA-2019-D-1536,Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework Guidance for Industry; Draft Guidance,Other,Guidance,2026-05-13T04:00:00Z,2026,5,2026-05-13T04:00:00Z,,2026-05-13T15:23:30Z,,1,0,09000064b92d0c28
FDA-2019-D-1536-0014,FDA,FDA-2019-D-1536,Request for Extension from Pharmaceutical Research and Manufacturers of America (PhRMA),Other,Request for Extension,2019-07-15T04:00:00Z,2019,7,2019-07-15T04:00:00Z,,2019-07-15T16:20:56Z,,0,0,0900006483d7cb9c
FDA-2019-D-1536-0001,FDA,FDA-2019-D-1536,Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2019-06-21T04:00:00Z,2019,6,2019-06-21T04:00:00Z,2019-08-21T03:59:59Z,2019-08-22T01:05:17Z,2019-13221,0,0,0900006483d2f6be
FDA-2019-D-1536-0002,FDA,FDA-2019-D-1536,Opioid Analgesic Drugs: Considerations for Benefit- Risk Assessment Framework; Guidance for Industry; Draft Guidance,Other,Guidance,2019-06-20T04:00:00Z,2019,6,2019-06-20T04:00:00Z,,2024-11-12T23:02:42Z,,1,0,0900006483d481b3